Cargando…
Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy
Immune checkpoint blockade therapies, especially those targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) have achieved impressive clinical responses in multiple types of cancers. To optimize the therapeutic effect of the checkpoint antibodies, many strategies including target...
Autores principales: | Li, Liyan, Miao, Qianwei, Meng, Fanqiang, Li, Baoqi, Xue, Tianyuan, Fang, Tianliang, Zhang, Zhirang, Zhang, Jinxie, Ye, Xinyu, Kang, Yang, Zhang, Xingding, Chen, Qian, Liang, Xin, Chen, Hongbo, Zhang, Xudong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058713/ https://www.ncbi.nlm.nih.gov/pubmed/33897897 http://dx.doi.org/10.7150/thno.48868 |
Ejemplares similares
-
Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
por: Meng, Fanqiang, et al.
Publicado: (2022) -
In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity
por: Lin, Zhongda, et al.
Publicado: (2023) -
The mechanism of lauric acid-modified protein nanocapsules escape from intercellular trafficking vesicles and its implication for drug delivery
por: Jiang, Lijuan, et al.
Publicado: (2018) -
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
por: Yan, Xinyu, et al.
Publicado: (2018) -
Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
por: Zou, Jianxuan, et al.
Publicado: (2015)